{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T05:54:41Z","timestamp":1771998881219,"version":"3.50.1"},"reference-count":35,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,12,9]],"date-time":"2019-12-09T00:00:00Z","timestamp":1575849600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015731","name":"Bayer Yakuhin","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015731","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","strokejournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Stroke and Cerebrovascular Diseases"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.jstrokecerebrovasdis.2019.104584","type":"journal-article","created":{"date-parts":[[2020,1,23]],"date-time":"2020-01-23T08:21:11Z","timestamp":1579767671000},"page":"104584","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Clinical Risk Factors of Thromboembolic and Major Bleeding Events for Patients with Atrial Fibrillation Treated with Rivaroxaban in Japan"],"prefix":"10.1016","volume":"29","author":[{"given":"Susumu","family":"Miyamoto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takanori","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takanari","family":"Kitazono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jyoji","family":"Nakagawara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuo","family":"Minematsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9147-6113","authenticated-orcid":false,"given":"Yuji","family":"Murakawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanghun","family":"Iwashiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makiko","family":"Takeichi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7870-541X","authenticated-orcid":false,"given":"Yoko","family":"Kidani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yutaka","family":"Okayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiyuki","family":"Sunaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8551-434X","authenticated-orcid":false,"given":"Shoichiro","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Yamanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jstrokecerebrovasdis.2019.104584_bib0001","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1161\/CIRCULATIONAHA.113.005119","article-title":"Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study","volume":"129","author":"Chugh","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.jstrokecerebrovasdis.2019.104584_bib0002","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/nrcardio.2014.118","article-title":"Global epidemiology of atrial fibrillation","volume":"11","author":"Rahman","year":"2014","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.jstrokecerebrovasdis.2019.104584_bib0003","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.ijcard.2008.06.029","article-title":"Prevalence of atrial fibrillation in the general population of Japan: an analysis based on periodic health examination","volume":"137","author":"Inoue","year":"2009","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jstrokecerebrovasdis.2019.104584_bib0004","doi-asserted-by":"crossref","first-page":"2n","DOI":"10.1016\/S0002-9149(98)00583-9","article-title":"Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates","volume":"82","author":"Kannel","year":"1998","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jstrokecerebrovasdis.2019.104584_bib0005","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S0002-9343(02)01253-6","article-title":"A population-based study of mortality among patients with atrial fibrillation or flutter","volume":"113","author":"Vidaillet","year":"2002","journal-title":"Am J Med"},{"key":"10.1016\/j.jstrokecerebrovasdis.2019.104584_bib0006","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1253\/circj.CJ-66-0092","article-title":"Guidelines for pharmacotherapy of atrial fibrillation (JCS 2013)","volume":"78","year":"2014","journal-title":"Circ J"},{"key":"10.1016\/j.jstrokecerebrovasdis.2019.104584_bib0007","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jstrokecerebrovasdis.2019.104584_bib0008","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1253\/circj.CJ-12-0454","article-title":"Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation \u2013 the J-ROCKET AF study","volume":"76","author":"Hori","year":"2012","journal-title":"Circ J"},{"key":"10.1016\/j.jstrokecerebrovasdis.2019.104584_bib0009","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.1001\/jama.285.22.2864","article-title":"Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation","volume":"285","author":"Gage","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.jstrokecerebrovasdis.2019.104584_bib0010","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1378\/chest.09-1584","article-title":"Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on Atrial Fibrillation","volume":"137","author":"Lip","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.jstrokecerebrovasdis.2019.104584_bib0011","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1378\/chest.10-0134","article-title":"A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey","volume":"138","author":"Pisters","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.jstrokecerebrovasdis.2019.104584_bib0012","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1253\/circj.CJ-14-0144","article-title":"Validation of CHA2DS2-VASc and HAS-BLED scores in Japanese patients with nonvalvular atrial fibrillation: an analysis of the J-RHYTHM Registry","volume":"78","author":"Okumura","year":"2014","journal-title":"Circ J"},{"key":"10.1016\/j.jstrokecerebrovasdis.2019.104584_bib0013","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1253\/circj.CJ-14-1378","article-title":"Oral anticoagulation in Japanese patients with atrial fibrillation \u2013 insight to the use of non-vitamin K antagonist oral anticoagulants","volume":"79","author":"G\u00f3mez-Molina","year":"2015","journal-title":"Circ J"},{"key":"10.1016\/j.jstrokecerebrovasdis.2019.104584_bib0014","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/joa3.12034","article-title":"Design and baseline characteristics of the Xarelto Post-Authorization Safety & Effectiveness Study in Japanese Patients with Atrial Fibrillation (XAPASS)","volume":"34","author":"Ogawa","year":"2018","journal-title":"J Arrhythm"},{"key":"10.1016\/j.jstrokecerebrovasdis.2019.104584_bib0015","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jjcc.2019.01.001","article-title":"Real-world outcomes of the Xarelto Post-Authorization Safety & Effectiveness Study in Japanese Patients with Atrial Fibrillation (XAPASS)","volume":"74","author":"Ikeda","year":"2019","journal-title":"J Cardiol"},{"key":"10.1016\/j.jstrokecerebrovasdis.2019.104584_bib0016","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"Schulman","year":"2005","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jstrokecerebrovasdis.2019.104584_bib0017","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s11239-019-01934-6","article-title":"Outcomes associated with under-dosing of rivaroxaban for management of non-valvular atrial fibrillation in real-world Japanese clinical settings","volume":"48","author":"Ikeda","year":"2019","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.jstrokecerebrovasdis.2019.104584_bib0018","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1056\/NEJMoa1904143","article-title":"Antithrombotic therapy for atrial fibrillation with stable coronary disease","volume":"381","author":"Yasuda","year":"2019","journal-title":"New Engl J Med"},{"key":"10.1016\/j.jstrokecerebrovasdis.2019.104584_bib0019","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S0140-6736(12)62177-1","article-title":"Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial","volume":"381","author":"Dewilde","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.jstrokecerebrovasdis.2019.104584_bib0020","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1161\/STROKEAHA.107.504993","article-title":"Dual antithrombotic therapy increases severe bleeding events in patients with stroke and cardiovascular disease","volume":"39","author":"Toyoda","year":"2008","journal-title":"Stroke"},{"key":"10.1016\/j.jstrokecerebrovasdis.2019.104584_bib0021","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1056\/NEJMoa1611594","article-title":"Prevention of bleeding in patients with atrial fibrillation undergoing PCI","volume":"375","author":"Gibson","year":"2016","journal-title":"New Engl J Med"},{"key":"10.1016\/j.jstrokecerebrovasdis.2019.104584_bib0022","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa1708454","article-title":"Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation","volume":"377","author":"Cannon","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jstrokecerebrovasdis.2019.104584_bib0023","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1817083","article-title":"Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation","volume":"380","author":"Lopes","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jstrokecerebrovasdis.2019.104584_bib0024","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(19)31872-0","article-title":"Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial","author":"Vranckx","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jstrokecerebrovasdis.2019.104584_bib0025","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jacc.2011.03.031","article-title":"A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study","volume":"58","author":"Fang","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jstrokecerebrovasdis.2019.104584_bib0026","first-page":"3258","article-title":"The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation","volume":"36","author":"O'Brien","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jstrokecerebrovasdis.2019.104584_bib0027","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.ahj.2005.04.017","article-title":"Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF)","volume":"151","author":"Gage","year":"2006","journal-title":"Am Heart J"},{"key":"10.1016\/j.jstrokecerebrovasdis.2019.104584_bib0028","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1253\/circj.CJ-18-0535","article-title":"Three-year clinical outcomes associated with warfarin vs. direct oral anticoagulant use among Japanese patients with atrial fibrillation-findings from the SAKURA AF registry","volume":"82","author":"Okumura","year":"2018","journal-title":"Circ J"},{"key":"10.1016\/j.jstrokecerebrovasdis.2019.104584_bib0029","article-title":"Assessing bleeding risk in 4824 Asian patients with atrial fibrillation: The Beijing PLA Hospital Atrial Fibrillation Project","volume":"6","author":"Guo","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.jstrokecerebrovasdis.2019.104584_bib0030","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(09)60503-1","article-title":"Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials","volume":"373","author":"Baigent","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.jstrokecerebrovasdis.2019.104584_bib0031","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/j.ijcard.2014.07.193","article-title":"Comparative evaluation of HAS-BLED and ATRIA scores by investigating the full potential of their bleeding prediction schemes in non-valvular atrial fibrillation patients on vitamin-K antagonists","volume":"176","author":"Abumuaileq","year":"2014","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jstrokecerebrovasdis.2019.104584_bib0032","article-title":"Correction to: Clinical risk factors of stroke and major bleeding in patients with non-valvular atrial fibrillation under rivaroxaban: the EXPAND study sub-analysis","author":"Sakuma","year":"2019","journal-title":"Heart Vessels"},{"key":"10.1016\/j.jstrokecerebrovasdis.2019.104584_bib0033","article-title":"Clinical risk factors of stroke and major bleeding in patients with non-valvular atrial fibrillation under rivaroxaban: the EXPAND study sub-analysis","author":"Sakuma","year":"2019","journal-title":"Heart Vessels"},{"key":"10.1016\/j.jstrokecerebrovasdis.2019.104584_bib0034","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.jjcc.2015.12.003","article-title":"Predictive factors for bleeding during treatment with rivaroxaban and warfarin in Japanese patients with atrial fibrillation \u2013 subgroup analysis of J-ROCKET AF","volume":"68","author":"Hori","year":"2016","journal-title":"J Cardiol"},{"key":"10.1016\/j.jstrokecerebrovasdis.2019.104584_bib0035","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2133\/dmpk.DMPK-12-RG-034","article-title":"Model-based dose selection for phase III rivaroxaban study in Japanese patients with non-valvular atrial fibrillation","volume":"28","author":"Tanigawa","year":"2013","journal-title":"DMPK"}],"container-title":["Journal of Stroke and Cerebrovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1052305719306834?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1052305719306834?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T22:03:36Z","timestamp":1764281016000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1052305719306834"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["S1052305719306834"],"URL":"https:\/\/doi.org\/10.1016\/j.jstrokecerebrovasdis.2019.104584","relation":{},"ISSN":["1052-3057"],"issn-type":[{"value":"1052-3057","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical Risk Factors of Thromboembolic and Major Bleeding Events for Patients with Atrial Fibrillation Treated with Rivaroxaban in Japan","name":"articletitle","label":"Article Title"},{"value":"Journal of Stroke and Cerebrovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jstrokecerebrovasdis.2019.104584","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"104584"}}